Therapeutic goals in Fabry disease: Recommendations of a European expert panel, based on current clinical evidence with enzyme replacement therapy

Christoph Wanner; Dominique P. Germain; Max J. Hilz; Marco Spada; Bruno Falissard; Perry M. Elliott

doi:10.1016/j.ymgme.2018.04.004

Therapeutic goals in Fabry disease: Recommendations of a European expert panel, based on current clinical evidence with enzyme replacement therapy

Christoph Wanner, Dominique P. Germain, Max J. Hilz, Marco Spada, Bruno Falissard, Perry M. Elliott

Research output: Contribution to journal › Comment/debate

15 Scopus citations

Original language	English
Pages (from-to)	210-211
Number of pages	2
Journal	Molecular Genetics and Metabolism
Volume	126
Issue number	3
DOIs	https://doi.org/10.1016/j.ymgme.2018.04.004
State	Published - Mar 2019
Externally published	Yes

Access to Document

10.1016/j.ymgme.2018.04.004

Cite this

@article{8066658b5f1d49b799d32f7eb109873c,

title = "Therapeutic goals in Fabry disease: Recommendations of a European expert panel, based on current clinical evidence with enzyme replacement therapy",

author = "Christoph Wanner and Germain, {Dominique P.} and Hilz, {Max J.} and Marco Spada and Bruno Falissard and Elliott, {Perry M.}",

note = "Funding Information: The development of the publications and the meetings of the international expert panel were sponsored by Sanofi Genzyme. The authors received editorial/writing support in the preparation of this manuscript from Rosalie Gadiot, PhD, and Tom Rouwette, PhD, of Excerpta Medica, which was funded by Sanofi Genzyme. The authors were responsible for all content and editorial decisions and received no honoraria related to the development of this publication. ",

year = "2019",

month = mar,

doi = "10.1016/j.ymgme.2018.04.004",

language = "English",

volume = "126",

pages = "210--211",

journal = "Molecular Genetics and Metabolism",

issn = "1096-7192",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - Therapeutic goals in Fabry disease

T2 - Recommendations of a European expert panel, based on current clinical evidence with enzyme replacement therapy

AU - Wanner, Christoph

AU - Germain, Dominique P.

AU - Hilz, Max J.

AU - Spada, Marco

AU - Falissard, Bruno

AU - Elliott, Perry M.

N1 - Funding Information: The development of the publications and the meetings of the international expert panel were sponsored by Sanofi Genzyme. The authors received editorial/writing support in the preparation of this manuscript from Rosalie Gadiot, PhD, and Tom Rouwette, PhD, of Excerpta Medica, which was funded by Sanofi Genzyme. The authors were responsible for all content and editorial decisions and received no honoraria related to the development of this publication.

PY - 2019/3

Y1 - 2019/3

UR - http://www.scopus.com/inward/record.url?scp=85046362578&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2018.04.004

DO - 10.1016/j.ymgme.2018.04.004

M3 - Comment/debate

C2 - 29724657

AN - SCOPUS:85046362578

SN - 1096-7192

VL - 126

SP - 210

EP - 211

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

IS - 3

ER -